SILO Stock Overview
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Silo Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.86 |
| 52 Week High | US$4.50 |
| 52 Week Low | US$0.83 |
| Beta | 1.37 |
| 11 Month Change | -22.52% |
| 3 Month Change | -40.69% |
| 1 Year Change | -50.29% |
| 33 Year Change | -90.88% |
| 5 Year Change | -95.35% |
| Change since IPO | -99.27% |
Recent News & Updates
Shareholder Returns
| SILO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.9% | 2.4% | 2.2% |
| 1Y | -50.3% | 16.2% | 31.7% |
Return vs Industry: SILO underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: SILO underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| SILO volatility | |
|---|---|
| SILO Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SILO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SILO's weekly volatility has decreased from 23% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 3 | Eric Weisblum | silopharma.com |
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems.
Silo Pharma, Inc. Fundamentals Summary
| SILO fundamental statistics | |
|---|---|
| Market cap | US$4.08m |
| Earnings (TTM) | -US$3.71m |
| Revenue (TTM) | US$72.10k |
53.5x
P/S Ratio-1.0x
P/E RatioIs SILO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SILO income statement (TTM) | |
|---|---|
| Revenue | US$72.10k |
| Cost of Revenue | US$5.84k |
| Gross Profit | US$66.26k |
| Other Expenses | US$3.78m |
| Earnings | -US$3.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.83 |
| Gross Margin | 91.90% |
| Net Profit Margin | -5,150.81% |
| Debt/Equity Ratio | 0% |
How did SILO perform over the long term?
See historical performance and comparison